🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "huge turning point" in the battle against increasingly resistant strains of the pathogen, according to researchers.

A Worldwide Health Concern

Gonorrhoea infections are on the rise around the world, with figures suggesting over 82 million infections each year. Notably increased rates are observed in Africa and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Public health authorities are increasingly worried about the surge in drug-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Therapies Gain Clearance

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers anticipate that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, gained clearance in close succession. This treatment, which is also used to treat UTIs, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin emerged from a new, not-for-profit approach for medication research. The charitable organization GARDP partnered with the drug firm Innoviva to see it through.

“This approval represents a huge turning point in the management of multidrug-resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Clinical Trial Data and Worldwide Availability

As per findings published in a major medical journal, the new drug cured more than 90% of uncomplicated infections. This establishes an equal footing with the existing first-line therapy, which combines two antibiotics. The research enrolled over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the authority to license and sell the drug in many developing nations.

Medical professionals treating patients have expressed positive views. The availability of a single-dose, oral treatment such as this is described as a "revolutionary step" for gonorrhoea control. This is deemed crucial to reduce the burden of the infection for people and to prevent the spread of highly drug-resistant gonorrhoea globally.